Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C4H9NO2S.ClH |
Molecular Weight | 171.646 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)[C@@H](N)CS
InChI
InChIKey=WHOHXJZQBJXAKL-DFWYDOINSA-N
InChI=1S/C4H9NO2S.ClH/c1-7-4(6)3(5)2-8;/h3,8H,2,5H2,1H3;1H/t3-;/m0./s1
Mecysteine is used as a mucolytic in respiratory disorders associated with productive cough. Mecysteine is known as a mucolytic
agent, it breaks down mucus. It works by breaking some
of the chemical bonds between the molecules in mucus. It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days. Mecysteine has also been given by inhalation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Mucus glycoproteins Sources: https://www.ncbi.nlm.nih.gov/pubmed/6185664 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VISCLAIR Approved UseVisclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm. |
|||
Primary | VISCLAIR Approved UseVisclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm. |
|||
Primary | VISCLAIR Approved UseVisclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm. |
PubMed
Title | Date | PubMed |
---|---|---|
The formation of malodorous dimethyl oligosulphides in treated groundwater: the role of biofilms and potential precursors. | 2001 May |
|
Redox inversion of helicity in propeller-shaped molecules derived from s-methyl cysteine and methioninol. | 2003 Mar 6 |
|
Kinetics and mechanistic studies of the hydrolysis of diisocyanate-derived bis-thiocarbamates of cysteine methyl ester. | 2006 Mar |
|
Electrospray ionization and triple quadrupole tandem mass spectrometry study of some biologically relevant homo- and heterodimeric cadmium thiolate conjugates. | 2006 Oct |
|
Facile discrimination of aldose enantiomers by reversed-phase HPLC. | 2007 Jun |
|
The uptake and fate of vanadyl ion in ascidian blood cells and a detailed hypothesis for the mechanism and location of biological vanadium reduction. A visible and X-ray absorption spectroscopic study. | 2008 Apr |
|
Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates. | 2009 Sep 21 |
|
A new method for the detection and characterization of alpha-lipoic acid mixed disulphides. | 2010 Apr |
|
Redetermination of di-μ-sulfido-bis-{[(2R)-2-acet-oxy-2-amino-ethane-1-thiol-ato-κN,S]oxidomolybdenum(V)}. | 2010 Apr 24 |
|
Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. | 2010 Aug |
|
hi2-1, a QTL which improves harvest index, earliness and alters metabolite accumulation of processing tomatoes. | 2010 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_12336.html
Curator's Comment: Mecysteine has also been given by inhalation.
It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6185664
The effects of L-cysteine methyl ester (Mecysteine) on behavior of mucus glycoproteins in canine tracheal secretory cells were investigated histologically and histochemically. Low concentrations (10(-7) and 10(-6)M) of L-cysteine methyl ester produced, as histological changes, decreases in the total goblet cell number and the thickness of the acini of submucosal glands, and an increase in the acinar inner diameter. On the other hand, L-cysteine methyl ester at 10(-5) and 10(-4)M produced an increase in the thickness of the acini and a slight decrease in the acinar inner diameter.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C017507
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
33RG619160
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
100000086184
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
18598-63-5
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
161611
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
m7126
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
5714-80-7
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
29144
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
SUB03110MIG
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
DTXSID9046520
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
235828
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
242-435-0
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
227-208-6
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
ALTERNATIVE |
ACTIVE MOIETY
SUBSTANCE RECORD